ArticleActa Cardiologica Sinica2026
Prognostic Value of Procalcitonin/Albumin Ratio in Predicting Outcomes After Transcatheter Aortic Valve Implantation.
Article in Acta Cardiologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transcatheter aortic valve implantation (TAVI) has emerged as preferred treatment for severe aortic stenosis in high-risk patients. Inflammatory and nutritional biomarkers have been increasingly investigated for their prognostic value. This study aimed to evaluate the utility of the procalcitonin/albumin ratio (PAR) in predicting 1-year mortality after TAVI. Methods: A retrospective cohort study was conducted on patients who underwent TAVI between June 2020 and January 2024. Pre-procedural serum procalcitonin and albumin levels were measured, and the PAR was calculated. Thirty-day and 1-year mortality and hospitalization for heart failure were defined as primary outcomes. Results: A total of 210 patients were included in the study. PAR was significantly higher in non-survivors compared to survivors (p < 0.0001). Receiver operating characteristic analysis demonstrated that the PAR had a moderate-to-good discriminatory ability for predicting 1-year mortality (area under the curve = 0.784 [95% confidence interval: 0.709-0.858]). In multivariate analysis, PAR was identified as an independent predictor of 30-day and 1-year mortality and hospitalization for heart failure. Conclusions: Our findings suggest that the PAR, as a combined marker of inflammation and nutritional status, may serve as a useful prognostic indicator in patients undergoing TAVI. The association between a higher PAR and increased mortality risk highlights the potential role of systemic inflammation and malnutrition in post-TAVI outcomes. The pre-procedural PAR appears to be a promising biomarker for predicting 1-year mortality after TAVI. Further prospective studies with larger cohorts are needed to validate these findings and explore potential clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.